CMV INFECTION IN KIDNEY TRANSPLANTATION
|
|
- Naomi Hoover
- 5 years ago
- Views:
Transcription
1 CMV INFECTION IN KIDNEY TRANSPLANTATION PIERRE MERVILLE CHU BORDEAUX - UNIVERSITÉ BORDEAUX SEGALEN UMR-CNRS 5164
2 SUMMARY: 1.Epidemiology in kidney transplantation 2.T T cell response: αβ and γδ lymphocytes 3.CMV monitoring: Why? How? Should I? 4.Indirects effects: Clinical impact 5.Update on CMV guidelines 6.Perspectives
3 AT THE ERA OF GENERALIZED PREVENTION, THE RISK OF INFECTION DEPENDS ON THE TREATMENT Universal Prophylaxis Preemptive Therapy Whole blood CMV qpcr D0 M3 M6 M12 Whole blood CMV qpcr: 1/week J0-M3, 1/month M3-M12 No threshold for anti-cmv therapy
4 MORE CMV INFECTIONS WITH THE PREEMPTIVE STRATEGY qpcr PRO 6 Mths D+R- D+R+ D-R+ n PRO 3 Mths PREE PRO PREE PRO PREE Khoury, ,0 54,0 18,0 54,0 27,0 75,0 98,0 Kliem, ,0 74,0 10,0 56,0 0,0 25,0 148,0 Reischig, ,0 83,0 56,0 96,0 60,0 86,0 70,0 Helentera, ,0 127,0 Humar, ,4 50,9 326,0 Van der Beek, ,0 69,0 78,0 Couzi, ,0 60,0 112,0 Witzke, ,6 53,8 3,6 22,2 296,0 Atabani, ,0 53,0 44,0 368,0 Mean (%) 37,2 51,3 68,3 24,9 62,6 22,7 50,4 1623,0 PRO : Prophylactic PREE: Preemptive
5 SIMILAR INCIDENCE OF CMV DISEASES qpcr PRO 6 Mths D+R- D+R+ D-R+ n Proph 3 Mths PREE PRO PREE PRO PREE Khoury, ,0 8,0 5,0 0,0 0,0 0,0 98,0 Kliem, ,0 Reischig, ,0 6,0 13,0 0,0 0,0 0,0 70,0 Helentera, ,0 127,0 Humar, ,1 36,8 326,0 Van der Beek, ,0 0,0 78,0 Couzi, ,0 26,0 112,0 Witzke, ,4 19,2 3,6 5,6 296,0 Atabani, ,5 2,5 0,9 368,0 Mean (%) na ,5 5,4 1,2 1,6 1623,0 PRO : Prophylactic PREE : Preemptive Na : Not applicable
6 SUMMARY: 1.Epidemiology in kidney transplantation 2.T T cell response: αβ and γδ lymphocytes 3.CMV monitoring: Why? How? Should I? 4.Indirects effects: Clinical impact 5.Update on CMV guidelines 6.Perspectives
7 DOMINATE THE MEMORY COMPARTMENTS OF EXPOSED SUBJECTS 70 % of viral peptides are able to generate a T cell response Sylwester et al, J. Exp. Med., 2005; 5:
8 IN R+ INDIVIDUALS, ANTI-CMV RESPONSE ENGAGES 4-5 % OF TOTAL CD4 AND CD8 LYMPHOCYTES Sylwester et al, J. Exp. Med., 2005; 5:
9 CONSEQUENCES OF CMV INFECTION: MEMORY INFLATION AND IMMUNE SENESCENCE? «CMV would represent the most important agent of effector T cell expansion and probably one of the most important causes for persistent immune activation in human aging» Vescovini et al, J. Immunol., 2007; 179:
10 γδ T CELL : A LYMPHOID STRESS SURVEILLANCE INVOLVED IN CMV INFECTION CMV Organ recipients CMV-driven expansion of γδ T cells % γδ T lymphocytes CMV+ CMV Months post-tx Innate-like features massive expansion of Vδ2 neg cells diverse TCR repertoire high expression of MHC-NKR high expression of CD16 (JCI, 1999) MCMV Early γδ expanders Late γδ expanders Adaptive-like features Week of infection p< very specific of CMV associated to infection resolution long-term blood signature of CMV TEMRA phenotype, concomitant to αβ expansion more rapid response in secondary infection (JID, 2001; Blood, 2008; JID, 2009, Blood 2012) Mouse model γδ protect αβ- mice from death γδ control virus (JEM, 2005; JASN, 2010; Cancer Res, 2009)
11 CMV INFECTION, A RELEVANT MODEL TO UNDERSTAND γδ T CELLS STRATEGY TO IDENTIFY NEW γδ TCR LIGANDS Patients Isolated T cell clones Reporter cell lines CMV TCR γδ TCR transfer Lentiviral transduction TCR-Ligand JRT3 CD69 mab screening TCR ligand identification stress stress CMV-infected or tumor cells Immunisation
12 DISCOVERY OF EPCR AS THE LIGAND OF THE CLONE LES LES (Vγ5V 5Vδ5) 5) Immunoprecipitation with 2E9 and M/MS EPCR Phospholipids Response (RU) 2E9+ line IgM 2E9 2E9- line (B Willcox s team) IgM 2E9 Endothelial Protein C Receptor EPCR sepcr directly binds to LES stcr EPCR TCR LES TCR MAU TCR αβ None Kd = 100 µm Time (s) Involved in coagulation (activator of protein C) α1 MHC-I-like molecule α2 Crystallization: associated with phospholipids expressed on endothelial cells (CMV targets) Increased expression on carcinoma cells α1 CD1d α2 (Willcox et al, Nat Immunol 2012) Antigen-presenting molecule Glyco- and phospho-lipid presentation to invariant NKT cells
13 SUMMARY: 1.Epidemiology in kidney transplantation 2.T T cell response: αβ and γδ lymphocytes 3.CMV monitoring: Why? How? Should I? 4.Indirects effects: Clinical impact 5.Update on CMV guidelines 6.Perspectives 13
14 WHY TO MONITORE SPECIFIC CMV IMMUNE RESPONSE? Prophylaxis of CMV infection : D+/R- patients : Which patients require a prolongation of prophylaxis? R+ patients : Is a treatment necessary for all patients? Treatment of CMV disease : Should we treat minor/transitory ADNemia? Following complete treatment of CMV disease, which patients require viral monitoring? When this patient is really cured?
15 HOW TO MONITORE SPECIFIC CMV IMMUNE RESPONSE? From Sester M, J Lab Med 2008;32: = quantiferon
16 SUMMARY OF THE STUDIES Assays Correlation with ADNemia Correlation with disease Clinical impact on treatment decision QuantiFERON-CMV (N=4) Yes Yes No data ELISPOT (N=5) Yes Yes No data Cytométry (N=9) Yes Yes No data Multimer HLA (N=1) No No No data - Limited number of patients (10-134), heterogeneous (R+ and D+R-) - No clear predictive threshold, weak sensitivity, influence of treatment - Probably more a matter of kinetics of the response than an immune threshold. Control Rechute
17 SUMMARY: 1.Epidemiology in kidney transplantation 2.T T cell response: αβ and γδ lymphocytes 3.CMV monitoring: Why? How? Should I? 4.Indirects effects: Clinical impact 5.Update on CMV guidelines 6.Perspectives
18 INDIRECT EFFECTS OF CMV INFECTION Infection (D+R-) Or Reactivation (R+) Fishman, NEJM, 2007 ; 357: CMV infection (DNAemia) DIRECT effects CMV disease INDIRECTS effects of CMV Opportunistic infections PTLD CMV Syndrome Invasive disease Hepatitis Colitis, Pneumonia, Rejection IF/TA Graft survival Arterial stenosis Patient survival Etc,
19 CMV AND ACUTE REJECTION : AN OLD DEBATE PRO : Sagedal S, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant. 2002;2(9): Toupance O, et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transpl Int. 2000;13(6): Reischig T, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8(1): Lowance D, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340(19): Dickenmann MJ, et al. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation. 2001;71(6): Pouteil-Noble C, et al. Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation. 1993;55(4): CONTRA : Couchoud C, et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation. 1998;65(5): Erdbruegger U, et al. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant. 2012;27(1): Drawbacks : Retrospective studies Timing between CMV and acute rejection Interplay between these two major events in kidney transplantation
20 EFFECT OF CMV VIREMIA ON SUBCLINICAL ACUTE REJECTION AND IFTA Patients and methods : 118 kidney transplant recipients with Prophylactic treatment (VACV 3 months) Preemptive treatment (VGCV) Protocol biopsy at M3 Résults : DNAemia incidence : 41 % Subclinical acute rejection : 29 % IFTA : 28 % Subclinical acute rejection : Is not associated to DNAemia IFTA Is associated to DNAemia > 2000 copies (OR: 3.8, p=0.02) Reischig et al, Transplantation 2009; 87:
21 SOME YEARS LATER LATE EFFECTS OF A PREEMPTIVE TREATMENT Patients : Preemptive (VGCV) : N=34 Preventive (VACV 3 mois) : N=36 Better patient survival in the preemptive group With less late-onset CMV infections Trend to less IFTA in the preemptive group (19 % vs 38 %) Reischig et al, J Am Soc Nephrol : 1588
22 EFFECT ON DNAEMIA ON GRAFT DYSFUNCTION AT 2 YEARS N=55 pediatric kidney transplants 22 % of subclinical CMV DNAemia during the first two years Prophylactic treatment for 3 à 12 months More IFTA on protocol biopsies in viremic patients Unless the prophylactic treatment Smith et al, J Am Soc Nephrol 2010, 21:
23 INDIRECT EFFECTS AT THE LIGHT OF ECOLOGICAL IMMUNOLOGY: CONCEPT OF TOLERANCE TO A PATHOGEN For each individual, a CMV infection has a fitness cost : Damage caused by the pathogen : direct effects Damage caused by host immune system : indirect effects Tolerance is the magnitude of these direct and indirect effects In transplantation, immunosuppressive treatment can differently modulate the level of tolerance Ruslan Medzhitov, Disease Tolerance as a Defense Strategy, Science, 2012, 335, 936 Ayres and Schneider, Tolerance of Infections, Ann Rev Immunol 2012, 30:
24 SUMMARY: 1.Epidemiology in kidney transplantation 2.T T cell response: αβ and γδ lymphocytes 3.CMV monitoring: Why? How? Should I? 4.Indirects effects: Clinical impact 5.Update on CMV guidelines 6.Perspectives
25 CMV MANAGEMENT FROM CONSENSUS TO CLINICAL PRACTICE International consensus guidelines on the management of cytomegalovirus in solid organ transplantation Transplantation Society International CMV Consensus Group. Transplantation Apr 15;89(7): Update October 2012
26 MANAGEMENT OF CMV INFECTION CONSENSUS RECOMMENDATIONS I Both universal prophylaxis and pre-emptive strategies are viable approaches for prevention of CMV disease (D+R- and R+). For centers or patients unable to meet the stringent logistic requirements required with a pre-emptive therapy strategy, prophylaxis is preferred. Where possible, 6 months may be preferable for D+/R- kidney recipients When a prophylaxis strategy is used for prevention in R+ patients (with either D+ or D-), 3 months of antiviral medication should be used When a pre-emptive therapy strategy is used, a sufficiently low threshold for initiation of treatment during pre-emptive therapy is recommended.
27 MANAGEMENT OF CMV INFECTION CONSENSUS RECOMMENDATIONS II Anti-viral medications used in kidney transplant: valganciclovir, intravenous ganciclovir, or high dose valacyclovir. Treatment of rejection (ALG, high dose steroids) should result in reinitiation of prophylaxis or pre-emptive therapy for 1 to 3 months The routine use of the hybrid strategy is not recommended at this time in any risk group Immune monitoring assays should continue to be improved for ease of use and standardization. Kotton CN, et al. Transplantation 2010; 89:
28 PERSPECTIVES WHO international standard +++ (UI/ML) Clinical studies on immune monitoring are required Maribavir and new medications (letermovir, cyclopropavir, CMX001) useful in anti-viral resistance Vaccines (anti-gb), humanized anti-cmv antibodies Modulation of immunosuppression: antiviral effects of mtor inhibitors.
29 MERCI POUR VOTRE ATTENTION
ESCMID Online Lecture Library. by author
Prevention of Cytomegalovirus infection following solid-organ transplantation: from guidelines to bedside Oriol Manuel, MD Infectious Diseases Service and Transplantation Center University Hospital and
More informationImmunomodulator y effects of CMV disease
Immunomodulator y effects of CMV disease Oriol Manuel MD Service of Infectious Diseases and Transplantation Center University Hospital of Lausanne Switzerland Outline The transplant troll The indirect
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. Optimizing use of organs from Increased Risk Donors
2017 CST-Astellas Canadian Transplant Fellows Symposium Optimizing use of organs from Increased Risk Donors Atual Humar, MD Atul Humar is a Professor in the Department of Medicine, University of Toronto.
More informationPrevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients
TRANSPLANTATION Prevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients Mohsen Nafar, 1 Azamolsadat Roshan, 2 Fatemeh Pour-Reza-Gholi, 1 Fariba Samadian, 1 Pedram
More informationDisclosures. CMV and EBV Infection in Pediatric Transplantation. Goals. Common Aspects CMV (Cytomegalovirus) and EBV (Epstein-Barr virus)
Disclosures I have financial relationships with the following companies: CMV and EBV Infection in Pediatric Transplantation Elekta Inc Lucence Diagnostics Spouse employed Spouse employed I will not discuss
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationEvaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients
Xavier University of Louisiana From the SelectedWorks of Ifeanyi Onor, PharmD, BCPS June, 2013 Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant
More informationCases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center
Cases: CMV, HCV, BKV and Kidney Transplantation Simin Goral, MD University of Pennsylvania Medical Center Disclosures Grant support: Otsuka Pharmaceuticals, Astellas Pharma, Angion, AstraZeneca, and Kadmon
More informationDiagnosis of CMV infection UPDATE ECIL
UPDATE ECIL-4 2011 Recommendations for CMV and HHV-6 management in patients with hematological diseases Per Ljungman, Rafael de la Camara, Hermann Einsele, Dan Engelhard, Pierre Reusser, Jan Styczynski,
More informationShiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School
CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation
More informationIMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar
IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences
More informationPlease submit supporting medical documentation, notes and test results.
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Valcyte (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationRobert B. Colvin, M.D. Department of Pathology Massachusetts General Hospital Harvard Medical School
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Robert B. Colvin Transplantation: Friendly organs in a hostile environment Robert B. Colvin,
More informationCytomegalovirus (CMV) remains one of the most common
SPECIAL FEATURE Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation Camille N. Kotton, 1,8 Deepali Kumar, 2 Angela M. Caliendo, 3 Anders Åsberg,
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. EBV Post Transplantation Implications and Approach to Management
2017 CST-Astellas Canadian Transplant Fellows Symposium EBV Post Transplantation Implications and Approach to Management Atul Humar, MD Atul Humar is a Professor in the Department of Medicine, University
More informationA Retrospective Comparison of the Safety and Efficacy of 3 months vs. 6 months
1 A Retrospective Comparison of the Safety and Efficacy of 3 months vs. 6 months Valganciclovir for Cytomegalovirus Prophylaxis in Renal Transplant Recipients Investigators: Ashley Masys, BScPharm, ACPR(c)
More informationWelcome and. Introductions
1 Welcome and Introductions 2 2 Levels of Evidence Quality of evidence on which recommendations are based: Grade I II-1 II-2 Definition Evidence from at least one properly randomized, controlled trial
More informationUse of Viral Load Testing in Managing CMV Infections in SOTR
Use of Viral Load Testing in Managing CMV Infections in SOTR Angela M. Caliendo, MD, PhD, FIDSA Professor and Vice Chair, Medicine Alpert Medical School of Brown University Providence, RI Disclosures Scientific
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationHigh-Dose Acyclovir for Cytomegalovirus Prophylaxis in Seropositive Abdominal Transplant Recipients
728296AOPXXX10.1177/1060028017728296Annals of PharmacotherapyMcCreary et al research-article2017 Research Report High-Dose Acyclovir for Cytomegalovirus Prophylaxis in Seropositive Abdominal Transplant
More informationProtein Biomarker Biomarker Discover y y in Organ Organ Transplantation A A Proteomics Proteomics Approach Tara r Sig del, Sig PhD 9/26/2011
Protein Biomarker Discovery in Organ Transplantation A Proteomics Approach Tara Sigdel, PhD 9/26/2011 Presented at the 2011 Stanford Mass Spectrometry Users Meeting For personal use only. Please do not
More informationEBV Protocol
EBV Protocol 8.26.14 Data From UNOS Summary Stats 1988-2014 CASU + 2009-2014 CAPC Organ Total PTLD Percent PTLD Percent PTLD in Literature Heart 294 21 7 3-9 Heart-Lung 34 3 9 16 Intestine 42 7 17 10-45
More informationBarry Slobedman. University of Sydney. Viruses in May 11 th May, 2013
Barry Slobedman University of Sydney Viruses in May 11 th May, 2013 Outline Human cytomegalovirus (CMV) impact on the community Three phases of infection Focus on the dormant (latent) phase of infection
More informationMECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW
MECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW YVON LEBRANCHU Service Néphrologie et Immunologie Clinique CHU TOURS ANTIGEN PRESENTING CELL CD4 + T CELL CYTOKINE PRODUCTION CLONAL
More informationDiagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape
Diagnosis and Management of Acute and Chronic Humoral Rejection Lars Pape Immunosuppression Acute rejection Chronic rejection Side effects Infections Nephrotoxicity Adult population Nearly all late rejection-related
More informationFOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1
1 Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF FOCiS 2 Lecture outline Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory
More informationEBV in HSCT 2015 update of ECIL guidelines
ECIL-6 EBV in HSCT 2015 update of ECIL guidelines Jan Styczynski (Poland, chair), Walter van der Velden (Netherlands), Christopher Fox (United Kingdom), Dan Engelhard (Israel), Rafael de la Camara (Spain),
More informationCurrent and Future Treatment of Cytomegalovirus Infection
Current and Future Treatment of Cytomegalovirus Infection Robin K. Avery MD, FIDSA, FAST Professor of Medicine, Division of Infectious Disease Johns Hopkins Disclosures Robin Avery MD has been a co-investigator
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationMicro 204. Cytotoxic T Lymphocytes (CTL) Lewis Lanier
Micro 204 Cytotoxic T Lymphocytes (CTL) Lewis Lanier Lewis.Lanier@ucsf.edu Lymphocyte-mediated Cytotoxicity CD8 + αβ-tcr + T cells CD4 + αβ-tcr + T cells γδ-tcr + T cells Natural Killer cells CD8 + αβ-tcr
More informationBidirectional Interaction between Cytomegalovirus and Hepatitis C Virus after Liver Transplantation: A Critical Review of the Clinical Evidence
Trends in Transplantation Transplant. 2008;2:148-56 2008;3 Bidirectional Interaction between Cytomegalovirus and Hepatitis C Virus after Liver Transplantation: A Critical Review of the Clinical Evidence
More informationThe new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials
The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials Carmen Lefaucheur 1 2 Banff 2015: Integration of HLA-Ab for improving
More informationMONOGRAFIA VALCYTE 5/2 30/3/04 17:31 Página 69 Bibliografía
Bibliografía Bibliografía 1. Bankier AT, et al. The DNA sequence of the human cytomegalovirus genome. DNA Seq. 1991; 2: 1-12. 2. Bean B. Cytomegalovirus. An update for primary care physicians. Postgrad
More informationCytomegalovirus (CMV) infection is among the most
CLINICAL AND TRANSLATIONAL RESEARCH Cytomegalovirus Serology and Replication Remain Associated With Solid Organ Graft Rejection and Graft Loss in the Era of Prophylactic Treatment Martin Stern, 1,11 Hans
More informationRegulatory Status FDA-approved indications: Valcyte is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.22 Subject: Valcyte Page: 1 of 5 Last Review Date: December 8, 2017 Valcyte Description Valcyte (valganciclovir)
More informationMicr-6005, Current Concepts of Immunology (Rutgers course number: 16:681:543) Spring 2009 Semester
Micr-6005, Current Concepts of Immunology (Rutgers course number: 16:681:543) (3 Credits) Spring 2009 Semester Course Director: (732-235-4501, ) Please note that this course is offered once every 2 years.
More informationSevere Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia
Severe Viral Related Complications Following Allo-HCT for Severe Aplastic Anemia Liat Shragian Alon, MD Rabin Medical Center, ISRAEL #EBMT15 www.ebmt.org Patient: 25-year-old male No prior medical history
More informationThe past 5 years has seen exciting advances related to the
Original Clinical ScienceçGeneral Downloaded from https://journals.lww.com/transplantjournal by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3pzrw1VmaZXQ+S1X5qzIxw8+AIlXMhR5CNF7trXzV+w4=
More informationBiology of Immune Aging
Biology of Immune Aging Jorg J. Goronzy Stanford University Immune deficiency Increase morbidity and mortality from infections Poor vaccine responses Cancer Immune Aging Chronic inflammation Coronary artery
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationTopic BKV Polyoma Virus
Topic 13.1. BKV Polyoma Virus Author: Helen Pilmore and Paul Manley GUIDELINES a. We suggest screening high risk kidney transplant recipients for BK polyoma virus (BKV) with quantitative plasma NAT. The
More informationLONDON S S GLOBAL UNIVERSITY. Post-transplant transplant infection: are we better prepared to face the enemy?
LONDON S S GLOBAL UNIVERSITY Post-transplant transplant infection: are we better prepared to face the enemy? Overview of presentation Briefly summarise viruses important after transplantation Short term
More informationT Cell Development II: Positive and Negative Selection
T Cell Development II: Positive and Negative Selection 8 88 The two phases of thymic development: - production of T cell receptors for antigen, by rearrangement of the TCR genes CD4 - selection of T cells
More informationCytomegalovirus in critically ill patients
! Cytomegalovirus in critically ill patients Frédéric Pène Medical ICU, Hôpital Cochin, AP-HP, Paris, France Université Paris Descartes, Sorbonne Paris Cité Institut Cochin, Inserm U1016, CNRS UMR-8104
More informationT Cell Activation, Costimulation and Regulation
1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family
More informationNatural Killer Cells: Development, Diversity, and Applications to Human Disease Dr. Michael A. Caligiuri
Natural Killer Cells: Development, Diversity, November 26, 2008 The Ohio State University Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute Columbus, Ohio, USA 1 Human
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationImmunology. Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency
Immunology Anas Abu-Humaidan M.D. Ph.D. Transplant immunology+ Secondary immune deficiency Transplant Immunology Transplantation is the process of moving cells, tissues or organs from one site to another
More informationImmunology: an overview Lecture
Slide #2: Immunology is sometimes regarded as part of microbiology department because it started there as an investigation of ways used to prevent against infectious agents (e.g. microorganisms ). However
More informationHYPERIMMUNOGLOBULIN and CMV- DNAemia IN PREGNANT WOMEN WITH PRIMARY CYTOMEGALOVIRUS INFECTION
HYPERIMMUNOGLOBULIN and CMV- DNAemia IN PREGNANT WOMEN WITH PRIMARY CYTOMEGALOVIRUS INFECTION Giovanni Nigro, Rome, Italy Stuart P Adler, Richmond, VA, USA To avoid fetal rejection (50% allograft) an estrogeninduced
More informationAPHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS
APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS GOW AREPALLY, MD MEDICAL DIRECTOR DUKE THERAPEUTIC APHERESIS SERVICE ASSOCIATE PROFESSOR, MEDICINE AMERICAN SOCIETY FOR APHERESIS MAY 25 TH 2013 OVERVIEW
More informationEvaluation of the QuantiFERON- CMV assay as a monitoring tool in solid organ and allogenic stem cell transplantation
Evaluation of the QuantiFERON- CMV assay as a monitoring tool in solid organ and allogenic stem cell transplantation Dr Grace Thompson A/Prof Mina John CMV in transplantation Major cause of morbidity and
More informationvalganciclovir, 450mg tablets, 50mg/ml powder for oral solution (Valcyte ) SMC No. (662/10) Roche Products Ltd
valganciclovir, 450mg tablets, 50mg/ml powder for oral solution (Valcyte ) SMC No. (662/10) Roche Products Ltd 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationXM-ONE XM-ONE XM-ONE. References XMO_V4.0_100205_CE.EU
Transplantation Cross match Transplantation Cross match XMO_V4._125_CE.EU Manufactured by: ABSORBER AB Address: Drottninggatan 33 SE-13 95 Stockholm, Sweden E-mail: info-ssp@olerup.com Tel: +46 8 5 89
More informationPage 4: Antigens: Self-Antigens The body has a vast number of its own antigens called self-antigens. These normally do not trigger immune responses.
Common Characteristics of B and T Lymphocytes Graphics are used with permission of Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com). Page 1: Introduction While B and T lymphocytes
More informationLate-Onset Cytomegalovirus (CMV) in Lung Transplant Recipients: Can CMV Serostatus Guide the Duration of Prophylaxis?
American Journal of Transplantation 2013; 13: 376 382 Wiley Periodicals Inc. C Copyright 2012 American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2012.04339.x
More information2/28/2017. Adult Heart Transplants Donor and Recipient Characteristics UNOS, Retransplant VCM. Other /2015 (N = 24,474)
1 46% 2% 3% 4% 0% 2% 2% CHD HCM ICM NICM RCM 49% 3% 3% 3% 1% 3% 3% Retransplant VCM 42% Other 35% 1/1982 6/2015 1/2009 6/2015 2016 JHLT. 2016 Oct; 35(10): 1149-1205 UNOS, 2017 Adult Heart Transplants Donor
More informationPrimary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis
American Journal of Transplantation 2010; 10: 2026 2032 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant
More informationLa risposta immune all infezione da virus ebola. Chiara Agrati, PhD
La risposta immune all infezione da virus ebola Chiara Agrati, PhD Pathogenetic mechanisms This virus infection is able to: - disable the immune system, preventing an effective protective immune response
More informationLack of Significant Co-Activation of BKV and CMV in Renal Transplant Patients: An Institutional Experience
Volume 1, Issue 1, pp: 1-6 Research Article Introduction Open Access Lack of Significant Co-Activation of BKV and CMV in Renal Transplant Patients: An Institutional Experience Minh-Thu Nguyen, BS 1, Phylicia
More informationIs it CVID? Not Necessarily HAIG TCHEUREKDJIAN, MD
Is it CVID? Not Necessarily HAIG TCHEUREKDJIAN, MD Current Paradigm of Pathogenesis Genetic defect(s) Molecular defect(s) Cellular defect(s) Clinical disease Current Paradigm of Pathogenesis Genetic defect(s)
More informationOriginal article Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients
Antiviral Therapy ; 7: (doi:.8/imp899) Original article Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients Martha T van der Beek
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationLecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells
1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:
More informationCellular Pathology of immunological disorders
Cellular Pathology of immunological disorders SCBM344 Cellular and Molecular Pathology Witchuda Payuhakrit, Ph.D (Pathobiology) witchuda.pay@mahidol.ac.th Objectives Describe the etiology of immunological
More informationPREVENTION AND TREATMENT OF BKV NEPHROPATHY Petra Reinke, Berlin, Germany. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy
PREVENTION AND TREATMENT OF BKV NEPHROPATHY Petra Reinke, Berlin, Germany Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Petra Reinke Department of Nephrology University Hospital
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationTranspla. antation. Associate Professor of Medical Virology Virology Research Center Shahid Beheshti University of Medical Sciences
Viral Mo olecular Diagno osis in Transpla antation Seyed Alireza Nadji, Ph.D. Associate Professor of Medical Virology Virology Research Center Shahid Beheshti University of Medical Sciences Which techniques
More informationCMV TREATMENT AND THE
CMV TREATMENT AND THE DILEMMA OF RESISTANCE Alissa Jade Wright, MD, FRCPC, MSc AMMI Canada Merck Integrated Symposium May 4, 2017 DISCLOSURES Educational grant money UBC-Pfizer UBC-Sunovion Advisory board
More informationReview of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology
Review of Rituximab and renal transplantation Dr.E Nemati Professor of Nephrology Introductio n Rituximab is a chimeric anti-cd20 monoclonal antibody. The CD20 antigen is a transmembrane nonglycosylated
More informationCanadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation Final Report
American Journal of Transplantation 2005; 5: 218 227 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2004 doi: 10.1111/j.1600-6143.2004.00692.x Canadian Society of Transplantation Consensus Workshop
More informationCytomegalovirus (CMV) Viral Load in Bronchoalveolar Lavage Fluid (BALF) and Plasma to Diagnose Lung Transplant Associated CMV Pneumonia
Cytomegalovirus (CMV) Viral Load in Bronchoalveolar Lavage Fluid (BALF) and Plasma to Diagnose Lung Transplant Associated CMV Pneumonia I.P. Lodding 1,2, H.H. Schultz 3, J.U. Jensen 1,5, C. Andersen 4,
More informationEffector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells
ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationHLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol
HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared
More informationThe clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation
Bone Marrow Transplantation, (1999) 23, 45 51 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt The clinical utility of CMV surveillance cultures and antigenemia
More informationHulya Caskurlu Fatma Y. Karadag Ferhat Arslan Yasemin Cag Haluk Vahaboglu. Abstract 1 INTRODUCTION ORIGINAL REPORT
Received: 21 August 2018 Revised: 15 September 2018 Accepted: 16 October 2018 DOI: 10.1111/tid.13016 ORIGINAL REPORT Comparison of universal prophylaxis and preemptive approach for cytomegalovirus associated
More informationTRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
More informationCytomegalovirus Infection in Immunocompetent and Renal Transplant Patients
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 386 Cytomegalovirus Infection in Immunocompetent and Renal Transplant Patients Clinical Aspects and T-cell Specific
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Valcyte) Reference Number: ERX.NPA.33 Effective Date: 06.01.15 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationDRUG MINIMISATION FROM BENCH TO BEDSIDE SOME LESSONS FROM THE RISET PROGRAM Hans-Dieter Volk, Berlin, Germany
DRUG MINIMISATION FROM BENCH TO BEDSIDE SOME LESSONS FROM THE RISET PROGRAM Hans-Dieter Volk, Berlin, Germany Chair: Josep M. Grinyo, Barcelona, Spain Marian Klinger, Wroclaw, Poland Prof Hans-Dieter Volk
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationVirological Surveillance in Paediatric HSCT Recipients
Virological Surveillance in Paediatric HSCT Recipients Dr Pamela Lee Clinical Assistant Professor Department of Paediatrics & Adolescent Medicine Queen Mary Hospital LKS Faculty of Medicine, The University
More informationChapter 10 (pages ): Differentiation and Functions of CD4+ Effector T Cells Prepared by Kristen Dazy, MD, Scripps Clinic Medical Group
FIT Board Review Corner September 2015 Welcome to the FIT Board Review Corner, prepared by Andrew Nickels, MD, and Sarah Spriet, DO, senior and junior representatives of ACAAI's Fellows-In-Training (FITs)
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationOriginal article Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients
Antiviral Therapy 2011; 16:1227 1235 (doi: 10.3851/IMP1879) Original article Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients
More informationTolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS
1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails
More informationA clear path forward COMING SOON THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
COMING SOON A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test which assesses organ
More informationStructure and Function of Antigen Recognition Molecules
MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and
More informationOptimal Length of Valganciclovir Prophylaxis after Solid Organ Transplantation
Trends in Transplantation Transplant. 2008;2:92-100 Optimal Length of Valganciclovir Prophylaxis after Solid Organ Transplantation Albert J. Eid 1,4, Carlos V. Paya 2 and Raymund R. Razonable 1-3 1 Division
More informationAutoimmunity & Transplantation. Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:
Autoimmunity & Transplantation Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Learning Objectives By the end of this lecture you will be able to: 1 Recognize
More informationImpact of Cytomegalovirus Disease in D+/R Kidney Transplant Patients Receiving 6 Months Low-Dose Valganciclovir Prophylaxis
American Journal of Transplantation 2011; 11: 1936 1942 Wiley Periodicals Inc. C 2011 The Authors Journal compilation C 2011 The American Society of Transplantation and the American Society of Transplant
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationMemory NK cells during mousepox infection. Min Fang, Ph.D, Professor Institute of Microbiology, Chinese Academy of Science
Memory NK cells during mousepox infection Min Fang, Ph.D, Professor Institute of Microbiology, Chinese Academy of Science Infectious Diseases are a Major Cause of Death Worldwide May 14 th 1796 Prevalence
More informationClinical Policy: Valganciclovir (Valcyte) Reference Number: CP.CPA.116 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Valcyte) Reference Number: CP.CPA.116 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationPatient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant
Patient Education Glossary of Terms For a kidney/pancreas transplant Glossary of Terms Page 18-2 Antibody A protein substance made by the body s immune system in response to a foreign substance. Antibodies
More information